REMEDY : BNSSG referral pathways & Joint Formulary

Home > Formulary : Adult > Chapters > 4. Central Nervous System >

BNSSG Adult Joint Formulary

4.3 Movement disorders

Last edited: 04-06-2024

4.3.1 Dystonias and other involuntary movements

First line drugs Second line drugs Specialist drugs Secondary care drugs

CNS Stimulants

Specific indication (TLS Blue):


  • Myoclonus


  • Essential tremor


  • Essential tremor


Monoamine Depleting Drugs

Tetrabenazine (TLS Amber Specialist Initiated)

  • Huntington's chorea


Neuroprotective Agents

Riluzole (TLS Amber 3 months) (SCP click here)

  • For Motor Neurone Disease as per NICE TA20
  • Riluzole liquid available for those patients with MND patients where all of the following criteria are met:
    • Those with Motor Neurone Disease who meet the criteria as described in NICE Technology Appraisal 20
    • Those with dysphagia having been assessed by SLT as needing a diet with stage II thickened fluids. This is in line with product characteristics.
    • For those where crushing tablets is not appropriate and use of this licensed liquid would be preferable to prevent PEG/RIG complications or where a PEG/RIG has been declined. 
    • Riluzole liquid will be initiated by a consultant, registrar or specialist nurse who is involved in the care of patients with Motor Neurone Disease 


Neurotoxins (Botulinum Toxins)

Botulinum toxin type A (Botox®, Dysport®, Xeomin®) (TLS Red)

  • Treatment of focal spasticity as per SPC. See Pathway Document.
  • Symptomatic relief of blepharospasm, hemifacial spasm and idiopathic cervical dystonia (spasmodic torticollis)
  • Botox® for use in migraine (chronic) according to NICE guidance TA260

Botulinum toxin type B (Neurobloc®) (TLS Red)


  • Botulinum toxin preparations are not directly interchangeable
  • Botulinum toxin is not approved for treatment for hyperhidrosis. For this indication exceptional funding should be sought on a case by case basis
  • To minimise the risk of errors botulinum toxin should be prescribed by brand name
  • Botulinum toxin type B is reserved for use in patients that have become tolerant to botulinum toxin type A


4.3.2 Parkinson's disease


Specific indication: (TLS Blue)


  • tablets are available on a named patient basis from IDIS





Catechol-O-Methyltransferase Inhibitors

Entacapone (TLS Amber Specialist Recommended)

Levodopa / Carbidopa / Entacapone (TLS Amber Specialist Recommended)

  • Brands include Stalevo®, Sastravi® and Stanek®

Opicapone (TLS Amber 3 months) (SCP click here)

  • As a second line option if Entacapone is ineffective or not tolerated

Tolcapone (TLS Red)

  • In combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations who have failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors (i.e. entacapone) (TLS Red)


Dopamine Precursors

Recommended: (TLS Green)

Co-beneldopa (Madopar®)

Co-careldopa (Sinemet®)

  • For untreated patients starting medication a dopamine agonist is usually recommended as first-line treatment - seek the advice of a specialist.

Co-careldopa + levodopa intestinal gel (Duodopa®) (TLS Red)

See NHS England Clinical Commissioning Policy: Levodopa-Carbidopa Intestinal Gel (LCIG) D04/P/e

Foslevodopa–foscarbidopa (TLS Red)

  • NICE TA934 Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms


Dopamine Receptor Agonists

Amantadine (TLS Amber 3 months) (SCP click here)

  • Also Formulary for the treatment of fatigue in multiple sclerosis (Unlicensed)

Apomorphine (TLS Red)

Bromocriptine (TLS Blue)

  • Established patients only

Cabergoline (TLS Amber Specialist Initiated)

  • Existing patients only

Pramipexole (including modified-release) (TLS Amber Specialist Initiated)  

  • Parkinson's disease
  • Annual vision test should be completed by Optometrist

Pramipexole (TLS Green)

  • Restless Legs Syndrome

Ropinirole (including modified-release & starter pack) (TLS Amber Specialist Initiated) 

  • Parkinson's disease

Ropinirole (TLS Blue)

  • Restless Legs Syndrome

Rotigotine (TLS Amber Specialist Recommended)

  • Can be started on advice of specialist - specialist may be Elderly Care/Neurology Consultant or Parkinson's' Disease Nurse Specialist. First prescription can come from GP.


Monoamine-oxidase B Inhibitors

Rasagiline (TLS Amber Specialist Initiated) 

  • Initiation by Consultant in Neurology and Care of the Elderly only

Selegiline (TLS Amber Specialist Initiated) 

Safinamide (TLS Amber 3 months) (SCP click here)



Methotrexate (TLS Amber 3 months) (SCP click here)

  • For a variety of neurological conditions such as Myasthenia Gravis and CIDP (unlicensed)

Mexiletine (NaMuscla®) (TLS Red)

  • NICE TA748 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders

Infliximab (intravenous & subcutaneous) (TLS Red)


Contact Us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.